Laboratory Corporation of America Holdings, known as Labcorp (NYSE:LH), is a global life sciences company specializing in comprehensive clinical laboratory services and drug development solutions. Headquartered in Burlington, North Carolina, the company offers a broad range of diagnostics and testing services that support patient care, disease management and biomedical research.
Labcorp’s core services cover routine and specialized clinical testing, anatomic pathology, molecular diagnostics and genomic sequencing. Its drug development division, Covance, provides end-to-end preclinical and clinical research services, including toxicology studies, clinical trial management and regulatory support. Through these offerings, Labcorp enables healthcare providers, biopharmaceutical firms and research institutions to accelerate drug discovery and deliver personalized medicine.
The company operates a network of more than 2,000 laboratories and patient service centers across North America, Europe, Asia-Pacific and Latin America. This global footprint allows Labcorp to partner with hospitals, clinics, academic centers and government agencies to enhance diagnostic capabilities and expand access to testing in key markets around the world.
Founded in 1978 with the formation of its first laboratory business, Labcorp has grown through strategic acquisitions and technology investments. A landmark moment came in 2014 when it acquired Covance, a leading contract research organization, broadening its research and development offerings. Today, Labcorp continues to invest in advanced diagnostics, data analytics and digital pathology to support innovation in precision health and improve patient outcomes.
